30 March 2020 — AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)…Original Article
You may also like
FDA Approves Miudella (copper intrauterine system) for...
FDA Approves Ctexli (chenodiol) for Cerebrotendinous...
FDA Approves Merilog (insulin-aspart-szjj), a...
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to...
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to...
FDA Approves Penmenvy (meningococcal groups A, B, C...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.